Squarepoint
TVTX icon

Squarepoint’s Travere Therapeutics TVTX Stock Holding History

Squarepoint’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.24M Sell
109,807
-90,304
-45% -$4M 0.01% 1412
2026
Q1 		$5.95M Sell
200,111
-119,547
-37% -$3.57M 0.01% 1373
2025
Q4 		$12.2M Buy
319,658
+205,181
+179% +$6.67M 0.01% 989
2025
Q3 		$2.74M Sell
114,477
-364,917
-76% -$6.86M ﹤0.01% 1853
2025
Q2 		$7.1M Buy
479,394
+262,370
+121% +$4.35M 0.01% 1262
2025
Q1 		$3.89M Buy
217,024
+199,468
+1,136% +$4.05M ﹤0.01% 1594
2024
Q4 		$306K Sell
17,556
-11,006
-39% -$195K ﹤0.01% 4131
2024
Q3 		$400K Buy
28,562
+12,982
+83% +$135K ﹤0.01% 3262
2024
Q2 		$128K Sell
15,580
-8,491
-35% -$57.2K ﹤0.01% 3753
2024
Q1 		$186K Sell
24,071
-101,708
-81% -$858K ﹤0.01% 3633
2023
Q4 		$1.13M Buy
125,779
+97,354
+342% +$709K ﹤0.01% 2438
2023
Q3 		$254K Sell
28,425
-131,873
-82% -$1.86M ﹤0.01% 3276
2023
Q2 		$2.46M Buy
160,298
+1,478
+0.9% +$26.9K 0.01% 1526
2023
Q1 		$3.57M Buy
158,820
+144,584
+1,016% +$3.07M 0.01% 1062
2022
Q4 		$299K Sell
14,236
-30,487
-68% -$646K ﹤0.01% 2581
2022
Q3 		$1.1M Buy
44,723
+30,360
+211% +$784K 0.01% 1700
2022
Q2 		$348K Buy
+14,363
New +$361K ﹤0.01% 2211
2021
Q4 		– Sell
-13,069
Closed -$317K – 3529
2021
Q3 		$317K Sell
13,069
-45,061
-78% -$828K ﹤0.01% 2233
2021
Q2 		$848K Buy
58,130
+27,621
+91% +$545K ﹤0.01% 1757
2021
Q1 		$762K Buy
30,509
+13,496
+79% +$373K ﹤0.01% 1724
2020
Q4 		$464K Buy
17,013
+5,496
+48% +$128K ﹤0.01% 1870
2020
Q3 		$213K Sell
11,517
-2,365
-17% -$46K ﹤0.01% 2048
2020
Q2 		$283K Buy
+13,882
New +$221K ﹤0.01% 1634
2019
Q3 		– Sell
-50,208
Closed -$1.01M – 2684
2019
Q2 		$1.01M Sell
50,208
-31,282
-38% -$618K 0.01% 1258
2019
Q1 		$1.84M Buy
81,490
+1,597
+2% +$35.3K 0.02% 806
2018
Q4 		$1.81M Buy
79,893
+35,137
+79% +$874K 0.02% 712
2018
Q3 		$1.29M Buy
44,756
+4,115
+10% +$118K 0.02% 883
2018
Q2 		$1.11M Buy
40,641
+28,941
+247% +$771K 0.01% 855
2018
Q1 		$262K Buy
+11,700
New +$279K ﹤0.01% 1377
2017
Q4 		– Sell
-12,030
Closed -$299K – 2348
2017
Q3 		$299K Buy
+12,030
New +$265K 0.01% 1187
2017
Q1 		– Sell
-12,428
Closed -$235K – 1920
2016
Q4 		$235K Buy
+12,428
New +$254K 0.01% 1315
2016
Q2 		– Sell
-10,400
Closed -$142K – 1352
2016
Q1 		$142K Sell
10,400
-4,800
-32% -$72.8K 0.01% 1045
2015
Q4 		$293K Buy
+15,200
New +$304K 0.03% 802

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Squarepoint's TVTX Position: Q2 2026 in Review

Squarepoint reduced its Travere Therapeutics (TVTX) stake by 45% in Q2 2026, selling an estimated $4M and leaving 109,807 shares worth $6.24M. The position accounts for 0.01% of the portfolio, ranked #1412.

Squarepoint first reported a position in TVTX in Q4 2015 and has held it in 33 quarters since. The position peaked at $12.2M in Q4 2025. 291 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Squarepoint held 109,807 shares of Travere Therapeutics worth $6.24M as of Q2 2026.
  • Squarepoint sold 90,304 Travere Therapeutics shares in Q2 2026, an estimated $4M.
  • Travere Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1412 holding.
  • Squarepoint first reported a position in Travere Therapeutics in Q4 2015 and has held it in 33 quarters since.
  • Squarepoint's Travere Therapeutics position peaked at $12.2M in Q4 2025.
  • 291 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.